
               
               
               CLINICAL PHARMACOLOGY
               
               
                  
                     
                     
                     Pharmacodynamics
                     
                        Naproxen is a nonsteroidal anti-inflammatory drug (NSAID) with analgesic and antipyretic properties. The mechanism of action of the naproxen anion, like that of other NSAIDs,is not completely understood but may be related to prostaglandin synthetase inhibition.
                     
                     
                  
               
               
                  
                     
                     
                     Pharmacokinetics
                     
                        Naproxen is rapidly and completely absorbed from the gastrointestinal tract with an in vivo bioavailability of 95%. The different dosage forms of naproxen are bioequivalent interms of extent of absorption (AUC) and peak concentration (Cmax); however, the products do differ in their pattern of absorption. These differences between naproxen productsare related to both the chemical form of naproxen used and its formulation. Even with the observed differences in pattern of absorption, the elimination half-life of naproxen isunchanged across products ranging from 12 to 17 hours. Steady-state levels of naproxen are reached in 4 to 5 days, and the degree of naproxen accumulation is consistentwith this half-life. This suggests that the differences in pattern of release play only a negligible role in the attainment of steady-state plasma levels.
                     
                     
                     
                        
                           
                           
                           Absorption
                           
                           
                              
                                 
                                 
                                 Immediate Release
                                 
                                    After administration of Naproxen Tablets, USP, peak plasma levels are attained in 2 to 4 hours.
                                 
                                 
                              
                           
                        
                     
                     
                        
                           
                           
                           Distribution
                           
                              Naproxen has a volume of distribution of 0.16 L/kg. At therapeutic levels naproxen is greater than 99% albumin bound. At doses of naproxen greater than 500 mg/day there isless than proportional increase in plasma levels due to an increase in clearance caused by saturation of plasma protein binding at higher doses (average trough Css 36.5, 49.2,and 56.4 mg/L with 500, 1000 and 1500 mg daily doses of naproxen, respectively). The naproxen anion has been found in milk of lactating women at a concentration equivalentto approximately 1% of maximum naproxen concentration in plasma (see PRECAUTIONS: Nursing Mothers).
                           
                           
                        
                     
                     
                        
                           
                           
                           Metabolism
                           
                              Naproxen is extensively metabolized in the liver to 6-0-desmethyl naproxen, and both parent and metabolites do not induce metabolizing enzymes. Both naproxen and 6-0-desmethyl naproxen are further metabolized to their respective acylglucuronide conjugated metabolites.
                           
                           
                        
                     
                     
                        
                           
                           
                           Excretion
                           
                              TThe clearance of naproxen is 0.13 mL/min/kg. Approximately 95% of the naproxen from any dose is excreted in the urine, primarily as naproxen (<1%), 6-0-desmethyl naproxen(<1%) or their conjugates (66% to 92%). The plasma half-life of the naproxen anion in humans ranges from 12 to 17 hours. The corresponding half-lives of both naproxenâ€™smetabolites and conjugates are shorter than 12 hours, and their rates of excretion have been found to coincide closely with the rate of naproxen disappearance from the plasma.Small amounts, 3% or less of the administered dose, are excreted in the feces. In patients with renal failure metabolites may accumulate (see WARNINGS: Renal Effects).
                           
                           
                        
                     
                     
                        
                           
                           
                           Special Populations
                           
                           
                              
                                 
                                 
                                 Geriatric Patients
                                 
                                    Studies indicate that although total plasma concentration of naproxen is unchanged, the unbound plasma fraction of naproxen is increased in the elderly, although the unboundfraction is < 1% of the total naproxen concentration. Unbound trough naproxen concentrations in elderly subjects have been reported to range from 0.12% to 0.19% of totalnaproxen concentration, compared with 0.05% to 0.075% in younger subjects. The clinical significance of this finding is unclear, although it is possible that the increase in freenaproxen concentration could be associated with an increase in the rate of adverse events per a given dosage in some elderly patients.
                                 
                                 
                              
                           
                           
                              
                                 
                                 
                                 Race
                                 
                                    Pharmacokinetic differences due to race have not been studied.
                                 
                                 
                              
                           
                           
                              
                                 
                                 
                                 Hepatic Insufficiency
                                 
                                    Naproxen pharmacokinetics has not been determined in subjects with hepatic insufficiency.
                                 
                                 
                              
                           
                           
                              
                                 
                                 
                                 Renal Insufficiency
                                 
                                    Naproxen pharmacokinetics has not been determined in subjects with renal insufficiency. Given that naproxen, its metabolites and conjugates are primarily excreted by the kidney,the potential exists for naproxen metabolites to accumulate in the presence of renal insufficiency. Elimination of naproxen is decreased in patients with severe renal impairment.Naproxen-containing products are not recommended for use in patients with moderate to severe and severe renal impairment (creatinine clearance <30 mL/min) (seeWARNINGS: Renal Effects).
                                    
                                 
                                 
                              
                           
                        
                     
                  
               
            
         